Researchers at the Hoag Family Cancer Institute have identified a blood-based RNA biomarker that detects early-stage ovarian cancer lesions with high accuracy, according to Science Et Vie.
The study, published on November 10 in Nature Medicine, offers a potential alternative to existing screening methods that often fail to catch the disease before it spreads.
The test targets a long non-coding RNA known as Tu-stroma, which is released by tumor cells into the bloodstream via tiny vesicles. According to the study, these molecules appear to weaken surrounding healthy cells, creating an environment that facilitates tumor growth.
The researchers focused on detecting tubal intraepithelial carcinomas (STICs), which are microscopic lesions in the fallopian tubes that precede high-grade serous carcinoma, the most lethal form of ovarian cancer.
In a validation group, the experimental test identified 92.3% of women with STIC lesions.
The study reported a performance score of 0.99, significantly outperforming the current standard blood marker, CA125, which reached a performance score of 0.59 in the same analysis. When tested against benign masses, the new biomarker maintained a performance score of 0.99, while CA125 dropped to 0.31.
The researchers believe the biomarker reflects a biological program activated early in the disease process rather than just the volume of tumor present. “Our goal is not only to detect earlier, but to prevent invasive cancer from appearing,” Esha Madan, a lead researcher on the study, said.
Despite these results, the test remains experimental and was evaluated using stored blood samples.
Rajan Gogna, a co-author of the study, cautioned that a negative result currently cannot rule out the presence of STIC lesions or justify delaying recommended surgical interventions, such as the removal of fallopian tubes in high-risk patients. The team is now preparing prospective studies to track patients over time to further validate the marker’s clinical utility.
What are STIC lesions?
STICs, or tubal intraepithelial carcinomas, are microscopic cancer precursors found in the fallopian tubes. They are difficult to detect via standard imaging or blood tests and are often discovered incidentally during unrelated surgeries.
Why is this test considered an improvement over CA125?
The new RNA test showed higher accuracy in identifying early-stage lesions and distinguishing them from benign conditions.
Unlike CA125, which can fluctuate due to menstruation or endometriosis in premenopausal women, the Tu-stroma marker did not show systematic elevations in inflammatory diseases tested by the researchers.
What is the next step for this research?
The research team is organizing prospective clinical studies to monitor individuals both with and without genetic risk factors for ovarian cancer. These trials will determine the test’s reliability in a real-world clinical setting before it can be used for routine screening.
The Hoag Family Cancer Institute, part of Hoag Hospital in Orange County, California, operates a translational research program led by Dr. Rajan Gogna, its Director of Translational Research. The institute runs over 100 clinical trials and was ranked the best health system in Orange County. An eight-year, international, multi-institutional study led by its researchers produced the Tu-stroma findings published in Nature Medicine.
Related reading